Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis

Oncogene. 2017 Jul 6;36(27):3797-3806. doi: 10.1038/onc.2017.6. Epub 2017 Feb 20.

Abstract

Metastases remain the major cause of death from cancer. Recent molecular advances have highlighted the importance of metabolic alterations in cancer cells, including the Warburg effect that describes an increased glycolysis in cancer cells. However, how this altered metabolism contributes to tumour metastasis remains elusive. Here, we report that phosphorylation-induced activation of lactate dehydrogenase A (LDHA), an enzyme that catalyses the interconversion of pyruvate and lactate, promotes cancer cell invasion, anoikis resistance and tumour metastasis. We demonstrate that LDHA is phosphorylated at tyrosine 10 by upstream kinases, HER2 and Src. Targeting HER2 or Src attenuated LDH activity as well as invasive potential in head and neck cancer and breast cancer cells. Inhibition of LDH activity by small hairpin ribonucleic acid or expression of phospho-deficient LDHA Y10F sensitized the cancer cells to anoikis induction and resulted in attenuated cell invasion and elevated reactive oxygen species, whereas such phenotypes were reversed by its product lactate or antioxidant N-acetylcysteine, suggesting that Y10 phosphorylation-mediated LDHA activity promotes cancer cell invasion and anoikis resistance through redox homeostasis. In addition, LDHA knockdown or LDHA Y10F rescue expression in human cancer cells resulted in decreased tumour metastasis in xenograft mice. Furthermore, LDHA phosphorylation at Y10 positively correlated with progression of metastatic breast cancer in clinical patient tumour samples. Our findings demonstrate that LDHA phosphorylation and activation provide pro-invasive, anti-anoikis and pro-metastatic advantages to cancer cells, suggesting that Y10 phosphorylation of LDHA may represent a promising therapeutic target and a prognostic marker for metastatic human cancers.

MeSH terms

  • Animals
  • Anoikis / drug effects
  • Antineoplastic Agents / pharmacology
  • Benzodioxoles / pharmacology
  • Breast Neoplasms / enzymology*
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Cell Proliferation
  • Enzyme Activation
  • Female
  • Humans
  • Isoenzymes / genetics
  • Isoenzymes / metabolism
  • L-Lactate Dehydrogenase / genetics
  • L-Lactate Dehydrogenase / metabolism*
  • Lactate Dehydrogenase 5
  • Lymphatic Metastasis
  • Mice, Nude
  • Neoplasm Invasiveness
  • Neoplasm Transplantation
  • Phosphorylation
  • Protein Processing, Post-Translational*
  • Quinazolines / pharmacology
  • Reactive Oxygen Species
  • Receptor, ErbB-2 / metabolism
  • src-Family Kinases / metabolism

Substances

  • Antineoplastic Agents
  • Benzodioxoles
  • Isoenzymes
  • Quinazolines
  • Reactive Oxygen Species
  • saracatinib
  • L-Lactate Dehydrogenase
  • Lactate Dehydrogenase 5
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • src-Family Kinases